Impact of transduction towards the proliferation and migration as well as the transduction efficiency of human umbilical cord-derived late endothelial progenitor cells with nine recombinant adeno-associated virus serotypes

[1]  M. Simionescu,et al.  Combinatorial approach for improving the outcome of angiogenic therapy in ischemic tissues. , 2015, Biomaterials.

[2]  R. Samulski,et al.  Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. , 2015, Human gene therapy.

[3]  M. Goligorsky.  Endothelial progenitor cells: from senescence to rejuvenation. , 2014, Seminars in nephrology.

[4]  R. Samulski,et al.  Recombinant Adeno-Associated Virus Utilizes Host Cell Nuclear Import Machinery To Enter the Nucleus , 2014, Journal of Virology.

[5]  H. Klenk,et al.  Sialic Acid Receptors of Viruses , 2013, Topics in current chemistry.

[6]  M. Porteus,et al.  A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype , 2013, Virology Journal.

[7]  J. S. Park,et al.  Transfection of VEGF(165) genes into endothelial progenitor cells and in vivo imaging using quantum dots in an ischemia hind limb model. , 2012, Biomaterials.

[8]  R. Samulski,et al.  Cytoplasmic Trafficking, Endosomal Escape, and Perinuclear Accumulation of Adeno-Associated Virus Type 2 Particles Are Facilitated by Microtubule Network , 2012, Journal of Virology.

[9]  K. High,et al.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges , 2011, Nature Reviews Genetics.

[10]  M. Hallek,et al.  Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors. , 2010, Experimental hematology.

[11]  Kenneth I. Berns,et al.  Gene Therapy Using Adeno-Associated Virus Vectors , 2008, Clinical Microbiology Reviews.

[12]  F. Wurm,et al.  High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells , 2007, Biotechnology Letters.

[13]  J. Grieger,et al.  Production and characterization of adeno-associated viral vectors , 2006, Nature Protocols.

[14]  M. Simons.  Angiogenesis: where do we stand now? , 2005, Circulation.

[15]  W. Hauswirth,et al.  Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. , 2005, Human gene therapy.

[16]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[17]  A. Luttun,et al.  De novo vasculogenesis in the heart. , 2003, Cardiovascular research.

[18]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[19]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[20]  James M. Allen,et al.  Adeno-Associated Virus Type 6 (AAV6) Vectors Mediate Efficient Transduction of Airway Epithelial Cells in Mouse Lungs Compared to That of AAV2 Vectors , 2001, Journal of Virology.

[21]  G. Hunninghake,et al.  Rate limiting steps of AAV transduction and implications for human gene therapy. , 2001, Current gene therapy.

[22]  R. Samulski,et al.  Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors , 2000, Journal of Virology.

[23]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[24]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[25]  M. Weitzman,et al.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis , 1996, Journal of virology.

[26]  J. Grieger,et al.  Adeno-associated virus vectorology, manufacturing, and clinical applications. , 2012, Methods in enzymology.

[27]  K. High,et al.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Douglas Losordo,et al.  Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. , 2005, Advances in genetics.